Actinium Pharmaceuticals Inc (ATNM) Kâr Dağıtımı

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.